NCT06735833Active, not recruiting
MMA Embolization for Refractory Chronic Migraine
Feasibility Study to Evaluate the Initial Safety and Effectiveness of TRUFILL n-BCA Liquid Embolic System in Middle Meningeal Artery Embolization for the Preventive Treatment of Refractory Chronic Migraine
Source: ClinicalTrials.gov · Last updated 3 Nov 2026
Brief summary (registry, in English)
This is a prospective, multi-center, feasibility study to investigate safety and effectiveness of TRUFILL n-BCA liquid embolic system in bilateral middle meningeal artery (MMA) embolization for the treatment of refractory chronic migraine.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 31 (actual)
- First submitted
- 4 Dec 2024
- Start date
- 23 Apr 2025
- Primary completion date
- 25 Dec 2026
- Lead sponsor
- Cerenovus, Part of DePuy Synthes Products, Inc.
- Diseases
- Migraine
- NCT number
- NCT06735833
What you commit to
- Study type: Interventional
- Participants enrolled: 31
- From 23 Apr 2025 to the primary completion date, 25 Dec 2026
- 8 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- Participant Inclusion Criteria, Candidates for this study must meet ALL the following inclusion criteria:
- Patient is between 18 and 65 years of age (inclusive) at the time of consent
- Age of onset of Chronic Migraine \<= 64 years
- Age of onset of migraine diagnosis \< 50 years
- Patient has a current diagnosis of refractory migraine
- Patient has a current diagnosis of Chronic migraine
- Participant Exclusion Criteria, Candidates will be excluded from participation if ANY of the following apply:
- Patients with a history for the last 2 years of other primary headache types, or secondary headache types except medication overuse headache
- Patients with diagnosis of hemiplegic migraine or migrainous infarct
- Patients with current regular use of Opioids, Cannabis, Medical Marijuana, etc
- Women who are pregnant, lactating, or who are of childbearing age
- Current involvement in an investigational (drug, device, etc.) clinical trial that may confound study endpoints. Participants in observational, natural history, and/or epidemiological studies not involving intervention are eligible. Sponsor approval is required
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (8)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Buffalo Medical Center Coordinator of this site? Confirm its status | Buffalo | United States | Unknown status |
| Hartford Hospital Coordinator of this site? Confirm its status | Hartford | United States | Unknown status |
| Semmes Murphey Foundation Coordinator of this site? Confirm its status | Memphis | United States | Unknown status |
| West Virginia University Coordinator of this site? Confirm its status | Morgantown | United States | Unknown status |
| Mount Sinai Coordinator of this site? Confirm its status | New York | United States | Unknown status |
| Thomas Jefferson University Hospital Coordinator of this site? Confirm its status | Philadelphia | United States | Unknown status |
| Stony Brook University Medical Center Coordinator of this site? Confirm its status | Stony Brook | United States | Unknown status |
| John Muir Physician Network Clin. Research Center Coordinator of this site? Confirm its status | Walnut Creek | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.